title: Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis.
abstract: Recent studies analysing immunogenetics and immune mechanisms controlling susceptibility to chronic bacterial infection in bronchiectasis implicate dysregulated immunity in conjunction with chronic bacterial infection. Bronchiectasis is a structural pathological end-point with many causes and disease associations. In about half of cases it is termed idiopathic, because it is of unknown aetiology. Bronchiectasis is proposed to result from a 'vicious cycle' of chronic bacterial infection and dysregulated inflammation. Paradoxically, both immune deficiency and excess immunity, either in the form of autoimmunity or excessive inflammatory activation, can predispose to disease. It appears to be a part of the spectrum of inflammatory, autoimmune and atopic conditions that have increased in prevalence through the 20th century, attributed variously to the hygiene hypothesis or the 'missing microbiota'. Immunogenetic studies showing a strong association with human leucocyte antigen (HLA)-Cw*03 and HLA-C group 1 homozygosity and combinational analysis of HLA-C and killer immunoglobulin-like receptors (KIR) genes suggests a shift towards activation of natural killer (NK) cells leading to lung damage. The association with HLA-DR1, DQ5 implicates a role for CD4 T cells, possibly operating through influence on susceptibility to specific pathogens. We hypothesize that disruption of the lung microbial ecosystem, by infection, inflammation and/or antibiotic therapy, creates a disturbed, simplified, microbial community ('disrupted microbiota') with downstream consequences for immune function. These events, acting with excessive NK cell activation, create a highly inflammatory lung environment that, in turn, permits the further establishment and maintenance of chronic infection dominated by microbial pathogens. This review discusses the implication of these concepts for the development of therapeutic interventions.
authors.affiliation: Lung Immunology Group, Section of Infectious Diseases and Immunity, Hammersmith Campus, Department of Medicine, Centre for Respiratory Infection, Imperial College London, UK. r.boyton@imperial.ac.uk
authors.forename: R J
authors.initials: RJ
authors.lastname: Boyton
authors.forename: C J
authors.initials: CJ
authors.lastname: Reynolds
authors.forename: K J
authors.initials: KJ
authors.lastname: Quigley
authors.forename: D M
authors.initials: DM
authors.lastname: Altmann
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000150:complications / Q000276:immunology*; D001987:Bronchiectasis / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002908:Chronic Disease; D020022:Genetic Predisposition to Disease; D015236:HLA-C Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000382:microbiology*; D008171:Lung Diseases / Q000276:immunology / Q000382:microbiology; D054892:Metagenome / Q000276:immunology*; D059013:Microbial Consortia; D011110:Polymorphism, Genetic; D054340:Receptors, KIR / Q000235:genetics / Q000276:immunology
chemical_list: D015236:HLA-C Antigens; D054340:Receptors, KIR